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Abstract
Background:  Tumors expressing a transforming growth factor-beta type I receptor (TβRI)
mutant with sequence deletions in a nine-alanine (9A) stretch of the signal peptide are reported to
be highly associated with disease progression. Expression of this mutant could interfere with
endogenous TGFβ signaling in the cell. However, little is known about the importance of the
remaining part of the signal peptide on the cellular function of TβRI.
Results: We cloned and identified four new in-frame deletion variants of TβRI, designated DM1
to DM4, in pleural effusion-derived tumor cells. Intriguingly, DM1 and DM2, with a small region
truncated in the putative signal peptide of TβRI, had a serious defect in their protein expression
compared with that of the wild-type receptor. Using serial deletion mutagenesis, we characterized
a region encoded by nucleotides 16–51 as a key element controlling TβRI protein expression.
Consistently, both DM1 and DM2 have this peptide deleted. Experiments using cycloheximde and
MG132 further confirmed its indispensable role for the protein stability of TβRI. In contrast,
truncation of the 9A-stretch itself or a region downstream to the stretch barely affected TβRI
expression. However, variants lacking a region C-terminal to the stretch completely lost their
capability to conduct TGFβ-induced transcriptional activation. Intriguingly, expression of DM3 in a
cell sensitive to TGFβ made it significantly refractory to TGFβ-mediated growth inhibition. The
effect of DM3 was to ablate the apoptotic event induced by TGFβ.
Conclusion: We identified four new transcript variants of TβRI in malignant effusion tumor cells
and characterized two key elements controlling its protein stability and transcriptional activation.
Expression of one of variants bestowed cancer cells with a growth advantage in the presence of
TGFβ. These results highlight the potential roles of some naturally occurring TβRI variants on the
promotion of tumor malignancy.
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Background
Malignant pleural effusions are good sources of trans-
forming growth factor β (TGFβ)-resistant tumor cells.
They frequently contain high levels of TGFβ of around 7.5
ng/mL [1]. However, epithelial tumor cells shedding or
migrating from local primary tumor sites are still alive and
grow well in the pleural effusions. Such cells are believed
to have some defects in the TGFβ receptors or in receptor-
mediated signaling pathways. Therefore, in the present
study, tumor cells derived from pleural effusions of
patients with lung cancer were chosen for examining the
gene expression and gene integrity of these receptors.
Type I TGFβ receptor (TβRI) is a key signaling receptor for
TGFβ to conduct Smad-mediated transcriptional activa-
tion in a cell. There are three major cell surface receptors
characterized for TGFβ ligands, designated TβRI, TβRII,
and TβRIII. In early signaling events, TGFβ binds to its cell
surface TβRII, followed by the recruitment and phosphor-
ylation of TβRI on a juxtamembrane glycine/serine (GS)-
rich domain. This phosphorylation results in the associa-
tion of R-Smads (Smad2 and Smad3) with a shared part-
ner, Smad4, to form heterotrimers that undergo nuclear
translocation to regulate TGFβ-responsive genes. The
putative function of TβRIII in these events is to facilitate
ligand binding to TβRI and TβRII [2]. Among these TGFβ
receptors, the type I plays a pivotal role in conducting the
TGFβ stimulus from cell surface into the nucleus to deliver
various biological outcomes. Functional disruption,
mutation, or aberrant expression of the TGFβ type I recep-
tor gene (Tgfbr1) is frequently associated with human dis-
eases, including cancers [3-6].
The Tgfbr1 gene is a tumor susceptible allele. Over 30% of
patients with ovarian cancer harbor somatic changes in
exons 1 to 6 [7-9]. Most changes are in-frame deletions or
insertion mutations in the nine-alanine (9A) stretch of the
putative signal peptide or missense mutations in the cata-
lytic kinase domain of the receptor. Other TβRI transcript
variants with sequence defect in the peptide have been
also reported in the rat kidney [10]. Notably, a gene vari-
ant with a three-alanine deletion (Tgfbr1-6A) in the 9A
stretch was found recently in a variety of cancers
[5,7,11,12], suggesting that this signal peptide is a suscep-
tible site for its gene mutation. Transfection of this variant
has been shown to convert TGFβ growth inhibitory sig-
nals into growth stimulatory signals in cells [13]. How-
ever, little is known about cellular functions of regions in
the signal peptide other than the 9A stretch.
We found four naturally occurring TβRI variants in three
patients with lung cancer. All variants have different in-
framed truncations in the signal peptide. Molecular dis-
section of the peptide using serial deletion mutagenesis
characterized two novel functional regions that partici-
pate in maintaining TβRI protein stability and receptor-
mediated transcriptional regulation in cells. Expression of
one of these variants in a cell could lead to its refractori-
ness to TGFβ, supporting an idea that naturally occurring
TβRI may have a role in tumor progression. Collectively,
our data suggest that the signal peptide of TβRI can be a
susceptible region for mutation resulting in TGFβ insensi-
tivity in cancer. Mutations occurred in different regions of
the signal peptide may display distinct TβRI defect modes
and suggest that the variants with these mutations may
represent potential therapeutic targets in cancers.
Results
Sequence deletions in the signal sequence of TβRI from 
effusion-derived tumor cells
Four new Tgfbr1 transcript variants were found in pleural
effusion-derived tumor cells. Total RNA was extracted
from patient cells CA427, CA528, CA1109, and from the
normal control cells, WI38 and HUVEC, and reverse-tran-
scribed into cDNA. Nested-PCR amplification reactions
using two pairs of primers, P1 and P2, located in the 5'
and 3' untranslated regions were performed to clone out
the endogenous Tgfbr1 transcript variants from the cells.
Gel electrophoresis of the amplicons revealed that at least
two additional Tgfbr1  transcript variants in the patient
cells. However, no extra band was detected in the normal
control cells, except for the 1.5 kb band representing the
wild-type Tgfbrl transcript (Fig. 1A). After gene cloning
and sequencing, four new in-framed deletion variants
were identified in the patients totally. The nucleotide
sequences of each variant in the truncated region are
shown in Figure 1B and listed in Table 1. They were desig-
nated as DM1 and DM2, with sizes around 1.5 kb, and
DM3 and DM4, with 0.3 kb and 0.9 kb deletions, respec-
tively (Fig. 1C). Intriguingly, all the variants had varied
nucleotide deletions in a sequence coding for the putative
signal peptide of TβRI. The proteins encoded by the DM3
and DM4 transcript variants also lack the transmembrane
domain and either partial or entire extracellular and GS-
rich regions, respectively. Thus, the data suggest that the
insensitivity of effusion tumor cells to TGFβ may be
caused by defects in the protein integrity of TβRI.
TβRI deletion variants are not contributed by somatic 
mutation
To detect the in vivo expression of Tgfbr1 transcript vari-
ants directly, ribonuclease protection assays were carried
out using individual antisense riboprobes for these
endogenous variants in CA1109 effusion cells. The data
shown in Figure 2 confirm that the existence of these four
transcript variants was not an artifact of the reverse tran-
scription or PCR reactions but that they occurred naturally
in the tumor cells. We subsequently genotyped Tgfbr1
gene from the tumor cells to determine if this deletion
event was caused by a somatic mutation. Gene amplifica-BMC Molecular Biology 2007, 8:72 http://www.biomedcentral.com/1471-2199/8/72
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The existence of Tgfbr1 transcript variants in pleural effusion-derived tumor cells Figure 1
The existence of Tgfbr1 transcript variants in pleural effusion-derived tumor cells. Panel A: RT-PCR. Total RNA was 
extracted from WI38, HUVEC, and pleural effusion-derived tumor cells followed by reverse transcription. Nested PCR reac-
tions amplified Tgfbr1 coding sequences using two pairs of primers, P1 and P2, as indicated at the top of Panel C. The resultant 
amplicons were resolved in a 1% agarose gel followed by gel purification, gene cloning, and direct sequencing. The nucleotide 
sequences flanking the truncated region(s) in each variant are marked at the top of Panel B. Panel C: Schematic illustration of the 
Tgfbr1 variants. DM1 and DM2 are in-frame variants lacking nucleotides 16–75 and 15–80, respectively, located in the signal 
sequence of the Tgfbr1 gene. DM3 and DM4 represent cytoplasmic variants lacking transmembrane and partial intracellular 
domains, as indicated.BMC Molecular Biology 2007, 8:72 http://www.biomedcentral.com/1471-2199/8/72
Page 4 of 15
(page number not for citation purposes)
tion was carried out by PCR amplification using pub-
lished primers [9] to target the intronic sequences of
exons 1, 2, or 3. The results obtained from direct sequenc-
ing showed no detectable mutations in the effusion tumor
and normal control cells (data not shown). Apparently,
the nucleotide deletions in the signal peptides sequence of
those transcripts do not occur at the gene structural level
but may be contributed by RNA editing or undefined
post-transcriptional cellular processes.
The N-terminal sequence of TβRI signal peptide controls 
its protein expression
Because no reliable antibody specific to TβRI was availa-
ble, the coding sequences of these variants were con-
structed and expressed as C-terminal HA-tagged proteins
in HEK293 and R1B cells. Western blotting analyses indi-
cated that the variants had great differences in their pro-
tein expression. Notably, DM1, lacking nucleotides 16–
75, and DM2, lacking nucleotides 15–80, were expressed
at extremely low levels in the cells as compared with the
expression of the wild-type control and the other two var-
iants (Fig. 3A). The same expression pattern was also
observed in R1B (Fig. 3A) and Cos-7 cells (data not
shown), indicating that the differential expression must
be cell type independent. An experiment using a plasmid
encoding green fluorescence protein co-transfected with
the individual variant genes showed that there were no
substantial differences in gene transfection efficiency,
ranging from 84.4% to 90.9% as determined by flow cyto-
metric analyses. Consistently, reverse transcriptase (RT)-
PCR analysis using P3 primers, as indicated in Figure 3,
showed that no distinction in the level of RNA transcript
among the exogenous variants was detected in the cells.
To determine if an element in the signal peptide might
affect TβRI expression, the sequence from nucleotide 16 to
nucleotide 117 was serially deleted as shown schemati-
cally in Figure 4A. The DS1 mutant lacks nucleotides 16–
51, which code for a peptide N-terminal to a 9A stretch.
The DS2 mutant protein has a peptide truncation in the
9A stretch itself, which has been reported to be susceptible
to nucleotide deletion in patients with several types of
cancer [5,7,13]. The DS3 mutant, with deletion of nucle-
otides 79–117, encodes a protein lacking a peptide C-ter-
minal to the 9A stretch. The data shown in Figure 4B
clearly indicate that deletion of the small sequence of
nucleotides 16–51 (DS1) is sufficient to impair the
expression of TβRI protein. Accordingly, both DM1 and
DM2 variants with deletion of this sequence also demon-
strated the same defect in their protein expression. In Fig-
ure 4C, RT-PCR analysis further confirmed that
differential protein expression among those deletion
mutants was not because of differences in the levels of
their transcripts. In contrast to DS1, the deletion of nucle-
otides 52–78 (DS2) or 79–117 (DS3) affected expression
only slightly. Thus, the peptide encoded by nucleotides
16–51 is a key element modulating the cellular expression
of the TβRI protein.
Role of the signal peptide on protein stability of TβRI
To determine if a sequence deletion of the signal peptide
might affect translation efficiency resulting in failure of
expression of TβRI, the DM1 was chosen because it had
the lowest protein expression among those variants. The
experiment coupling in vitro transcription and translation
demonstrated no distinct difference between DM1 and
the wild-type control on the translation efficiency (Fig.
5A).
To examine the possibility that a lack of the peptide
encoded by nucleotides 16–75 would affect the turnover
rate of the DM1 protein, its half-life and stability were
examined. The DM1 gene was transfected into HEK 293
cells followed by blocking translation machinery with
cycloheximide (CHX). The half-life of the DM1 protein
(about 30 min) was much shorter than that of the wild-
type protein (90 min) (Fig. 5B). These data are in agree-
ment with a previous report using pulse-chase metabolic
labeling [5]. Co-treatment with an ubiquitin-proteasome
inhibitor, MG132, and cycloheximide rescued the DM1
protein from degradation (Fig. 5C and 5D). The same
conclusion was obtained from an experiment using the
DS1 variant as a target protein (data not shown). How-
ever, this effect was not seen in the experiment using a 20S
proteasome inhibitor, lactacystin (Fig. 5D), indicating
that degradation of the DM1 and DS1 proteins is through
Table 1: Sequence deletions in Tgfbr1 variants with differential gel-mobility
Sample Fast Medium Slow
WI38 WT (6)
HUVEC WT (6)
CA427 ∆58–90/∆97–972 (5) WT (6)
CA528 ∆58–90/∆97–972 (5) WT (6)
CA1109 ∆58–90/∆97–972 (5) ∆46–117/∆344–574 (5) ∆16–75 (2) & ∆15–80 (4)
∆, nucleotide deletion; WT, wild-type; (n), number of clone sequencedBMC Molecular Biology 2007, 8:72 http://www.biomedcentral.com/1471-2199/8/72
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Detection of transcripts of Tgfbr1 variants by RNase protection analysis Figure 2
Detection of transcripts of Tgfbr1 variants by RNase protection analysis. Total RNA extracted from CA1109 effusion 
tumor cells were protected by corresponding antisense riboprobes, as indicated at the top. The riboprobes were synthesized 
by T7 RNA polymerase using T7 promoter-containing DNA fragment of individual variant as a template. The predicted pro-
tected fragments are 263 bp for D1 (DM1), 192 bp for D2 (DM2), 151 bp for D3 (DM3), and 90 bp for D4 (DM4). Lanes 5 and 
6: the mixed riboprobes (M) were incubated with (+) or without (-) RNase A/T1, respectively. Lanes 1–4: the total RNA (10 µg 
aliquots) was hybridized with individual purified antisense riboprobes and the protected fragments were resolved on a 6% acr-
ylamide/8 M urea sequencing gel. * Indicates an unidentified Tgfbr1 transcript variant in CA1109 tumor cells protected by the 
anti-DM3 riboprobe.
an ubiquitin-dependent process. Thus, the data clearly
indicate that the peptide encoded by nucleotides 16–51 is
a key element involved in TβRI protein stability.
Functional activation of TβRI variants in R1B cells
To test function of these naturally occurring TβRI variants
on TGFβ-mediated signaling, receptor-mediated tran-
scriptional activation was examined by a reporter gene
assay. The p3TP-Lux reporter containing a TPA-responsive
element and PAI-1 promoter was co-transfected with indi-
vidual variant genes into the TβRI-null cell line, R1B. In
response to TGFβ stimulation, receptor-mediated tran-
scriptional activation was determined from the corre-
sponding luciferase activity. Compared with
transcriptional activation mediated by wild-type TβRI
after protein normalization, truncation of a peptide
encoded by nucleotides 16–51 for the DS1 mutant did
not affect its receptor function (Fig. 6A). Similar results
were also seen in the DM1 and DM2 mutants with dele-
tion of this peptide. In contrast, truncation of a peptide C-
terminal to the 9A stretch (DS3) dramatically impaired its
capability to conduct TGFβ signaling. A consistent resultBMC Molecular Biology 2007, 8:72 http://www.biomedcentral.com/1471-2199/8/72
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Differential expression of TβRI variants Figure 3
Differential expression of TβRI variants. HEK 293 or R1B cells were transiently transfected with a plasmid encoding for 
haemagglutinin (HA)-tagged wild-type TβRI (WT), DM1, DM2, DM3, DM4 or vector control (VC), as indicated at the top. 
Untransfected (UN) cells were also included as control. After transfection for 24 h, the cells were trypsinized and divided into 
two groups for either Western blotting or RT-PCR analyses of HEK293 transfectants in Panel A or R1B cells in Panel B. For 
Western blotting analyses, the exogenous WT TβRI and its variants were detected with an antibody specific to the HA tag. For 
PCR reactions, a pair of primers, P3, complementary to C-terminal and HA tag sequences of exogenous TβRI-HAs to deter-
mine the transcript levels of WT and its variants as indicated. A β-Actin transcript and its encoded protein were used as loading 
controls, as indicated in the middle.
was also observed in the DM3 and DM4 variants lacking
this peptide. Thus, these data suggest that at least two
functional subdomains are located on the putative signal
peptide for TβRI to control its protein expression and
downstream signaling.
To examine if transcriptional activation induced by these
variants might affect cellular function, R1B cells were
transfected with individual variant genes and their
growths were measured using a standard MTT assay. In the
presence of TGFβ, the DM1, DM2, and DS1 variants sig-
nificantly suppressed the growth of R1B cells although
their protein expression levels were much lower than that
of the wild-type one (Fig. 6B). This data strongly suggests
that the expression levels are sufficient to transduct the
extracellular TGFβ signal, activate gene transcription, and
exert biological action in R1B cells. In contrast, lack of a
peptide C-terminal to the 9A stretch in DM3, DM4, and
DS3 almost abrogated their signaling capability, indicat-
ing that they are non-functional receptors.
Effects of variants on TGFβ-mediated growth regulation
To test if the coexistence of these variants might alter the
cellular function of TGFβ-sensitive cells, MCF-7 stableBMC Molecular Biology 2007, 8:72 http://www.biomedcentral.com/1471-2199/8/72
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Characterization of functional domains in the signal peptide of TβRI Figure 4
Characterization of functional domains in the signal peptide of TβRI. Panel A: Schematic illustration of the TβRI mutants 
with deletions in the signal peptide. Using wild-type Tgfbr1 (WT) as a template, the regions 5' or 3' to the 9A stretch sequence or 
the 9A stretch itself were truncated serially by site-directed deletion mutagenesis and designated as DS1, DS3, and DS2, 
respectively. HEK 293 cells were either untransfected (UN) or transfected with individual variants or vector control (VC) plas-
mid, as indicated at the top. The cells were divided into two groups for Western blotting or RT-PCR analyses 24 h after trans-
fection. Panel B: Western blotting. Each lysate (30 µg) was resolved on a 10% SDS-polyacrylamide gel, immunoblotted with HA-
specific antibody, and reprobed with anti-β-Actin antibody as a loading control. Panel C: RT-PCR. Total RNA was extracted from 
each transfectant and reverse transcribed. PCR reactions using P3 primers, as indicated at the bottom of Panel A, were utilized 
and the resultant amplicons were resolved on 1% agarose gels. A β-Actin transcript and its protein were used as loading con-
trols, as indicated on the right.BMC Molecular Biology 2007, 8:72 http://www.biomedcentral.com/1471-2199/8/72
Page 8 of 15
(page number not for citation purposes)
Protein stability of exogenous wild-type TβRI-HA and the DM1 variant in HEK293 cells Figure 5
Protein stability of exogenous wild-type TβRI-HA and the DM1 variant in HEK293 cells. Panel A: Translation effi-
ciency. A plasmid (1 µg) encoding for wild-type (WT) TβRI or DM1 was transcribed and translated in vitro using a coupled retic-
ulocyte lysate system. 35S-labeled proteins were resolved on a 10% SDS-polyacrylamide gel and visualized by autoradiography. 
The control plasmid (C) encoded for luciferase polypeptide (61 KDa). Panel B: Half-lives of wild-type TβRI and DM1. Cells were 
transfected with a plasmid encoding for wild-type TβRI (WT) or the DM1 variant. After 24 h transfection, the transfectants 
were treated with 50 µg/mL cycloheximide (CHX) for the designed time courses, as indicated at the top. WT (15 µg) and DM1 
(150 µg) transfectant lysates were analyzed by Western blotting using an anti-HA antibody. Panel C & D: Protein stability of DM1 
and DM2 associated with proteosome-related degradation. Transfectants were treated simultaneously with CHX and 5 µM, 20 µM 
MG132, or DMSO (vehicle control) for 30 min in Panel C. Transfectants treated with CHX and 20 µM MG132 or 10 µM lacta-
cystin (Lata) for 60 min were shown in Panel D. Protein levels were determined by Western blotting of WT, DM1, and DM2 
transfectant lysates using an anti-HA antibody. The same blot was reprobed with β-actin antibody as a control.BMC Molecular Biology 2007, 8:72 http://www.biomedcentral.com/1471-2199/8/72
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transfectants expressing individual TβRI variants were
established and cell growth was determined by MTT assay.
To eliminate possible artifacts associated with individual
cell clones, mixed transfectants were used. No measurable
difference on cell growth was observed among them in the
absence of TGFβ. However, the DM3 variant, surprisingly,
rescued 44.2% of growth suppression induced by TGFβ,
but only partial prevention was seen in the cells express-
ing DM4 (Fig. 7A). The action of DM3 is, at least partially,
attributed to the abolishment of TGFβ-induced apoptotic
event (Fig. 7B). On the other hand, as expected for DM1
and DM2, expression of either variant only produced a
slight difference from the control in the presence of TGFβ.
This may result from two possibilities. First, MCF-7 cells
have endogenous TGFβ receptors and intact downstream
signaling pathways to respond to TGFβ stimulation.
Increasing expression of exogenous signaling molecule(s)
is not always proportional to enhance the signaling mag-
nitude or biological outcomes [12,14]. Second, it might
be caused by saturated signaling capacity in the cells. Fur-
thermore, the expression level of DM1 or DM2 is quite
low and probably barely affects endogenous signaling in
TGFβ-responsive MCF-7 cells. In summary, these results
suggest that the existence of some TβRI variants in cancer
cells can bestow them with a growth advantage in a tumor
microenvironment such as that in malignant pleural effu-
sions with high levels of TGFβ.
Discussion
The type I receptor of TGFβ (TβRI) has a central role to
transmit TGFβ stimulation into the nucleus by activating
its downstream Smad- and non-Smad-mediated pathways
and modulating gene transcriptions to conduct its biolog-
ical effects in cells [15,16]. Functional disruption, muta-
tion, or aberrant expression of the Tgfbr1 gene could cause
many human diseases, including cancers [3-6]. In the
present study, we identified two additional functional ele-
ments in the signal peptide of TβRI beside published
mutations in the 9A stretch. Sequence loss or deletion of
a 12-residue peptide upstream to the 9A stretch, which is
encoded by nucleotides 16–51, showed a dramatic
impairment of TβRI expression because of its labile pro-
tein stability. On the other hand, a 13-residue peptide
immediately downstream to the stretch is apparently
involved in receptor-mediated signaling activation. In
contrast, removal of the 9A stretch itself had only a mild
effect on the protein expression and function of TβRI.
Intriguingly, Pasche et al. recently reported that deletion
of three alanine residues in the stretch conferred certain
advantages for tumor growth and was associated with the
malignancy of colorectal cancer [13]. Our study also dem-
onstrated that the presence of the DM3 variant could
counteract TGFβ action. These findings disclose an unex-
pected additional complexity in the response of tumor
cells to TGFβ-mediated growth regulation.
In contrast to previously reported TβRI variants, the four
newly discovered truncated forms defined in this study are
apparently not caused by somatic mutations. Germ-line
predisposing or cancer-associated somatically acquired
mutations are usually considered the major cause for mal-
function of the Tgfbr1 gene. Those mutations are com-
Transcription activation induced by TβRI variants Figure 6
Transcription activation induced by TβRI variants. 
Panel A. Transcriptional activation of TβRI variants. R1B cells 
were transiently transfected with 1 µg of either wild-type 
(WT) TβRI or truncated variants, as indicated in the bottom, 
1 µg of p3TP-Lux, and 0.05 µg of pRL-TK plasmid which was 
used to correct the differences in transfection efficiency 
between experiments. After transfection for 24 h, the cells 
were treated with TGFβ1 (5 ng/mL) for 24 h and luciferase 
activities in each lysates were determined using a dual-luci-
ferase reporter assay system (Promega). Data are the mean 
± SEM luciferase activities of four independent experiments 
normalized to individual protein level. Panel B. Effects of TβRI 
variants on TGFβ-induced cell growth. R1B cells were trans-
fected with each variant gene as indicated. The cell growth 
rates of the transfectants in the presence or absence of 
TGFβ1 were determined using standard MTT assays as 
described in the "Methods" section. Data are presented as 
the mean ± SEM of OD550 absorbance values of three inde-
pendent experiments.BMC Molecular Biology 2007, 8:72 http://www.biomedcentral.com/1471-2199/8/72
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posed of nucleotide transversion, insertion, and deletion
mutations. Around 30% of patients with ovarian cancer
bear a dinucleotide insertion in exon 5 of the Tgfbr1 gene
[9]. Another tumor-susceptible allele is Tgfbr1-6A. A meta-
analysis of 12 case-control studies by Pasche et al. [4] indi-
cates that Tgfbr1-6A  carriers have an increased risk of
colon, breast, and ovarian cancers compared with non-
carriers. In addition, there was a much higher frequency of
this allele found in colorectal tumor tissue than in germ-
line DNA extracted from the same patients [13], suggest-
ing that acquisition of Tgfbr1-6A allele may be contributed
by cancer-associated somatic deletions. However, this
clinical correlation between the frequency of this allele
and increased cancer risk is quite controversial since other
studies did not reach the same conclusion [17-19]. One
possible interpretation for this is that Tgfbr1-6A is also a
common polymorphism in healthy individuals (11.2% to
19.7%) [11]. Hence, the frequency between cancer
patients and controls is not distinctly different. A meta-
analysis of case-control studies for heterogeneity from dif-
ferent groups may be marginally significant. Intriguingly,
neither our laboratory nor others [20] have found this
mutant allele in patients with lung cancer. Hence, acquisi-
tion of lung cancer-associated mutations to TβRI may be
through post-transcriptional processes rather than
because of sequence defects in its genomic DNA. One
plausible mechanism for this is RNA editing, as several
mammalian tumor-associated transcript mutants can be
generated through this process [21-23].
RNA editing is a widespread phenomenon in eukaryotes
and it involves insertions, deletions, or nucleotide conver-
sion leading to post-transcriptional base changes in
mRNA and tRNA [24]. This cellular process is also
observed in mammalian transcripts and some of them are
associated with tumorigenesis such as in the glutamate
receptor [21], Ptpn6 [22], and Wt-1 [23]. Consistent with
our finding, Choi [10] also reported an insertion of four
or five amino acid residues in the carboxyl terminus of
extracellular domain of naturally occurring rat Alk-5
(Tgfbr1) transcripts. This finding further strengthens our
hypothesis that cancer cells may modulate their sensitivity
to TGFβ by generation of its receptor variants through a
post-transcriptional process and interfere with endog-
enous existing signaling. At least, DM3 in this study may
be such a case.
Sequence deletions in the Tgfbr1 transcripts are not merely
through a single biological process. In addition to the
truncations in the signal peptide, the deletion of nucle-
otides 344–574 in the sequence for DM3 and nucleotides
97–972 in that for DM4 are consequences of major alter-
native gene splicing. Alignment of the published human
Tgfbr1 gene sequence [25] with the nucleotide sequences
encoding these two variants revealed that the deletions
occur precisely between exons 2 and 4 for DM3 and
between exons 1 and 6 for DM4. Hence, generation of
these transcript variants is probably involved in at least
two post-transcriptional processes: alternative RNA splic-
ing or RNA editing or even a yet undefined biological
process.
Effects of DM3 on TGFβ-induced growth inhibition and cell  apoptosis Figure 7
Effects of DM3 on TGFβ-induced growth inhibition 
and cell apoptosis. Panel A: Cell growth. The MCF-7 trans-
fectants were seeded at a density of 5000 cells per well in 24-
well plates followed by TGFβ1 treatment or not for 96 h. 
The cell counts for each transfectants were quantified by a 
standard MTT assay. The results are presented as the means 
± SEM of three independent experiments. ** Indicates that 
the DM3 variant rescued the cells from TGFβ-induced 
growth suppression (P < 0.01). Panel B: TGFβ-induced cell 
apoptosis. Transfectants (2 × 105 cells) expressing DM3, DM4, 
or vector control (VC) were seeded and stimulated with (+) 
or without (-) 5 ng/mL of TGFβ1 for 72 h. The cells were 
collected and stained with Annexin V and propidium iodide 
for detection of apoptotic cells. The percentage of the apop-
totic cells in the total cell population was determined by flow 
cytometry. Data are presented as the fold increases in cell 
apoptosis compared with those of corresponding untreated 
cells.BMC Molecular Biology 2007, 8:72 http://www.biomedcentral.com/1471-2199/8/72
Page 11 of 15
(page number not for citation purposes)
Regulation of protein degradation requires accurate iden-
tification. Frequently, a small region of protein sequence
provides information that targets the protein for degrada-
tion such as the degradation motif of IκB [26], the stabil-
ity-regulating region of MOS [27], and the N-terminal
residues of some proteins [28,29]. The action for the deg-
radation is either mediated by ubiquitin-dependent [30]
or -independent [31] proteolytic pathways. Removal of
the 12-residue peptide upstream to the 9A stretch in the
DM1, DM2, and DS1 variants greatly shortened their pro-
tein half-lives (Fig. 5). Treatment with MG132, an ubiqui-
tin-proteasome inhibitor, but not of lactacystin, a highly
specific inhibitor of the 20S proteasome, rescued them
from degradation. Therefore, this 12-residue peptide
might have an indispensable role in the protection of TβRI
against ubiquitin-dependent protein degradation. The
protective role played by this peptide is probably to target
a newly synthesized polypeptide of TβRI onto the endo-
plasmic reticulum membrane and prevents it from pro-
longed exposure to cytoplasmic proteolytic machinery.
However, this is not the case for TGFBR1-6A. Pasche et al.
[13] showed that the removal of three alanine residues
from the 9A stretch did not measurably affect its mem-
brane targeting. Thus, the essential role of the 12-residue
peptide for membrane targeting of TβRI variants needs to
be clarified.
Additionally, a region C-terminal to the 9A stretch in the
signal peptide, ranging from residue 27 to residue 39, has
a tremendous effect on TβRI-mediated transcriptional
activation. Lack of this region in the DM3, DM4, and DS3
variants showed no dramatic difference from the wild-
type one in their protein expression, but all failed to con-
duct TGFβ signaling (Fig. 6). This result clearly indicates
the critical role of this region for the function of TβRI.
Based on amino terminal sequencing in a previous report
[13] or using a SignaIP program [32], the data indicate
that the major cleavage site of the putative signal peptide
is located between residues 33 and 34. Hence, loss of the
cleavage site could be a potential factor accounting for
DS3's refractoriness to TGFβ. One plausible speculation is
that the signal peptides un-cleaved from these variants,
and in turn, interfere with their ability to bind with ligand.
However, there might be other residues in this region crit-
ical for the receptor function.
The co-existence of TβRI variants might confer survival
benefits to tumor cells. This hypothesis is supported by
our present data, showing that the expression of DM3
enabled MCF-7 cells to resist TGFβ-induced growth inhi-
bition markedly. A similar observation was also reported
in the TGFBR1-6A variant [13]. However, in contrast to
this variant, the DM3 protein not only loses the truncated
region of DS3, but also lacks the transmembrane domain,
juxtamembrane region, and GS motif. In our gene
reporter and cell proliferation assays in R1B cells (Fig. 6),
those data further confirm that DM3 is a non-functional
receptor and mainly localized in the cytosol. One previ-
ous study by Saitoh et al. [33] showed that a deletion
mutant lacking its juxtamembrane region could be still
associated with TβRII and transduce TGFβ signaling.
Therefore, we speculate that this DM3 variant can modu-
late TGFβ-mediated signaling activation by competing
with endogenous wild-type TβRI in the cells for associa-
tion with the type II receptor and thereby blocking some
downstream signaling pathways. This working hypothesis
is currently supported by our unpublished data, showing
that DM3 could significantly abolish TGFβ-induced JNK
activation and have a potential role in tumorigenesis.
However, another possibility that secondary signals gen-
erated by this variant may directly deregulate the TGFβ-
induced cell apoptosis should also not be ruled out since
it still contains an intact serine/threonine kinase domain.
Compared to DM3, DM4 loses several kinase sub-
domains, particularly for subdomains III-V, which have
been shown to include a key region for the transduction
of TGFβ signaling [34]. The expression of this variant
could also rescue TGFβ-induced growth suppression in a
cell although the magnitude of the blocking effect was
much weaker than that of DM3. If the molecular mecha-
nism mediated by DM4 is the same as by DM3 remains to
be elucidated.
Although the involvement of TGFBR1-6A and our newly
discovered variants in tumorigenesis has not been sub-
stantially validated in vitro or in vivo studies, this implica-
tion seems to be supported by published data from several
clinical studies. Thus, Chen et al. [8] performed genotyp-
ing for the Tgfbr1 gene in 34 patients with ovarian cancer.
The data showed that 7 out of 34 (21%) patients had
either deleted or point mutations in the truncated regions
of DM3 or DM4. Wang, et al. [9] found that around 31.3%
of ovarian cancer patients had a 2-nucleotide insertion at
codons 276–277 (nucleotides 825–831), also located in
this region. Thus, these findings suggest that mutations in
Tgfbr1 are likely responsible for human ovarian carcino-
genesis. However, the evidence from our and Zhang's [20]
laboratories obviously indicate that mutations of Tgfbr1
probably do not result from defects in its DNA level.
Hence, for association of Tgfbr1 mutations with lung can-
cer, a large-scale case-control study on mutations of its
transcript is required to test any correlation between the
frequency of mutated transcripts and their potential to
cause malignancy.
Conclusion
Loss of functional TβRI resulting in insensitivity to TGFβ
is frequently associated with tumor malignancy [35,36].
The disclosure of these two hitherto undiscovered regions
on the signal peptide of TβRI in this study adds pivotalBMC Molecular Biology 2007, 8:72 http://www.biomedcentral.com/1471-2199/8/72
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knowledge to the molecular understanding of its protein
expression and receptor function and provides an alterna-
tive molecular target for monitoring disease progression.
First, these data demonstrate that a small deletion in the
putative signal peptide of TβRI is a common feature for
the pleural effusion-derived tumor cells we have exam-
ined so far, but this is not found in normal control cells.
Second, the serial site-directed deletion mutagenesis
resolved an indispensable role for TβRI protein stability of
the 12-residue peptide upstream to the 9A stretch of the
signal peptide. Deletion of a 13-residue peptide down-
stream to the 9A sequence produced serious impairment
to receptor-mediated transcriptional activation. Third,
study of the effects of these naturally occurring variants on
cell growth has provided a plausible interpretation for
how effusion tumor cells can survive in a microenviron-
ment enriched with TGFβ. Finally, these observations
indicate that a small sequence deletion in the signal pep-
tide can cause distinct consequences for TβRI protein
expression or receptor function and suggest that DM3
might act as an oncogene, regulating TGFβ-induced path-
ways that may be amenable to therapeutic intervention.
Methods
Cell culture
HEK 293 cells were cultured in Dulbecco's modified
Eagle's medium (Invitrogen, Carlsbad, CA) supplemented
with 10% fetal bovine serum (FBS), penicillin (100 units/
ml), and streptomycin (100 µg/ml). TβRI-deficient R1B,
MCF-7, and TβRI variant-transfected cells were cultured in
Minimum Essential Medium in the presence of 10% FBS,
10 mM sodium pyruvate, and 1 mM nonessential amino
acids (Invitrogen). The CA427, CA528, and CA1109 puri-
fied primary effusion tumor cells were cultured in ACR-4
medium [37] supplemented with 10% FBS for one or two
passages in vitro.
Sample processing
Pleural effusions were collected by thoracocentesis from
three patients with lung adenocarcinoma following the
tenets of the Helsinki declaration under the auspices of
the National Health Research Institutes (NHRI) Institu-
tional Review Board. The fluids were centrifuged within 2
h at 300 × g for 10 min to pellet the effusion cells. Separa-
tion of tumor cells from effusion-associated lymphocytes
was performed using serial gradient centrifugation with
Ficoll and Percoll (Pharmacia, Uppsala, Sweden) as
described previously [38]. The purity of tumor cells in the
fraction, as determined by cytological examination, was
between 80–90%.
RT-PCR and gene cloning
Total RNA from WI38 cells, human umbilical endothelial
cells (HUVECs), and effusion-derived tumor cells was
extracted using the High Pure RNA Tissue kit (Roche Diag-
nostics, Indianapolis, IN) and reverse-transcribed using
SuperScript III reverse transcriptase (Invitrogen) as
described in the manufacturer's instructions. Subse-
quently, nested-PCR reactions were performed to clone a
Tgfbr1 coding sequence containing AUG start and UAA
stop codons using two pairs of gene-specific primers, P1
and P2 (Fig. 1C), located in the 5' – and 3' -untranslated
regions of the Tgfbr1 gene (NCBI database: NM_004612).
To facilitate gene amplification of the highly GC-rich TβRI
sequences, Advantage-GC polymerase (Clontech Co.,
Mountain View, CA) was used according to the manufac-
turer's instructions. Subsequently, PCR products were
cloned into pIVEX2.5 (Roche) to generate C-terminus HA-
tagged wild-type TβRI and its variants. Subsequently, the
gene inserts were subcloned into the pcDNA3.1 vector
(Invitrogen) at the 5' -Hind III and 3' -Apa  I sites to
improve protein expression in HEK 293 cells.
To generate mutants with truncations in the signal pep-
tide, site-directed deletion mutagenesis reactions were car-
ried out using designed primers (Table 2) and priming
wild-type  Tgfbr1  gene to truncate nucleotides 16–51
(DS1), 52–78 (DS2), or 79–117 (DS3), as described pre-
viously [39].
For quantification of Tgfbr1  transcript variants in the
transfected HEK293 or R1B cells, reverse transcriptase-
PCR (RT-PCR) reactions were performed using a pair of
primer, P3, as indicated in Figure 3, aligned with 3'-coding
sequence of Tgfbr1 and the HA tag sequence.β-Actin was
acted as an internal control for those reactions.
Western blotting
HA-tagged TβRI variants and β-Actin were analyzed by
Western blotting. HEK 293 or R1B cells were transiently
transfected with each gene construct using Lipofectamine
(Invitrogen) or ExGene500 (Fermantas, Hanover, MD),
respectively. For increasing protein expression, transfected
R1B cells were infected with T7 vaccinia viruses as
described previously [40]. The transfectants were lysed 24
h after the transfection in a lysis buffer [10 mM Na2HPO4,
150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycho-
late, 0.1% SDS, 10 mM NaF] supplemented with 1 × pro-
tease inhibitor cocktail (Roche Diagnostics).
Approximately 15 or 150 µg of the lysates were resolved
by electrophoresis in 10% or 15% SDS-containing poly-
acrylamide gels, as indicated in the figure legends. The
proteins were blotted onto nitrocellulose transfer mem-
branes (Schleicher & Schuell, Keene, NH) and probed
with anti-HA-tag (Covance, Berkeley, CA), or anti-β-Actin
(Sigma, St. Louis, MO) antibodies. The immuno-com-
plexes were detected by probing with anti-mouse or -rab-
bit IgG conjugated with HRP (Jackson ImmunoResearch,
Cambridgeshire, UK) and visualized using the SuperSig-BMC Molecular Biology 2007, 8:72 http://www.biomedcentral.com/1471-2199/8/72
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nal chemiluminescence detection system (Pierce, Rock-
ford, IL).
Reporter gene assay
Receptor-mediated transcriptional activation of wild-type
TβRI and its truncated variants was determined by meas-
uring TGFβ-induced luciferase activity. Each gene con-
struct or a control plasmid was co-transfected into R1B
cells with the p3TP-Lux reporter gene using ExGene 500
(Fermentas). To normalize the transfection efficiency,
0.05 µg of the Renilla luciferase reporter plasmid pRL-TK
(Promega, Madison, WI) was also utilized in the experi-
ments. After 24 h, the transfectants were starved for 6 h by
changing for fresh media supplemented with 0.2% FBS,
and then treated with 5 ng/ml TGFβ1 (R&D systems, Min-
neapolis, MN) for 24 h. Firefly and Renilla luciferase activ-
ities in each transfected cell lysate were detected using
Dual-luciferase reporter system (Promega) in a TD-20/20
luminometer (Turner Designs, Sunnyvale, CA).
Flow cytometric analysis
Examination of transfection efficiency with different gene
constructs was performed by co-transfection with the
pEGFP plasmid encoding green fluorescent protein. One
microgram of each gene construct and 0.1 µg of pEGFP
were transfected into 3–5 × 105 cells and incubated for 24
h. Flow cytometric analyses were used to determine the
percentage of green fluorescence-positive cells in total cell
population using a FACSCalibur machine (BD Bioscience,
San Jose, CA).
For analysis of TGFβ-induced cell apoptosis, 2 × 105 sta-
ble-transfectants expressing the DM3, or DM4 variants
were seeded onto each well of 6-well plates and cultured
overnight at 37°C. After TGFβ1 treatment for 72 h, cells
were collected, washed with PBS twice, and stained with
Annexin V/propidium iodide (PI) according to manufac-
turer's instructions (BioVision, Mountain View, CA). The
results are presented as fold of increase in cell apoptosis as
compared with corresponding untreated cells.
Ribonuclease protection assay
The existence of Tgfbr1 naturally occurring transcript vari-
ants was confirmed by RNase protection analysis using
the RPA III kit (Ambion, Austin, TX). PCR reactions using
primers listed in Table 2 generated variant-specific ampli-
Table 2: List of primers used for reverse transcriptase-polymer chain reactions, site-directed deletion mutagenesis, and ribonuclease 
protection assay
Gene Sequence
RT-PCR
TβRI P1 S: 5'-CGAGGTTTGCTGGGGTGAGGCA-3'
AS: 5'-CTCAGTGAGGTAGAACAACTGACC-3'
P2 S: 5'-AACAAGCTTTCCACCATGGAGGCGGCGGT-3'
AS: 5'-GTTCATATCTTACATTTTGATGCCTTCCTGT-3'
β-Actin S: 5'-CCCTTTTTGTCCCCCAAC-3'
AS: 5'-CTGGTCTCAAGTCAGTGTACAGGT-3'
TβRI-HA P3 S: 5'-ATCTATGCAATGGGCTT-3'
AS: 5'-AGCGTAATCTGGAACATCGTA-3'
Mutagenesis
TβRI DS1 S: 5'-ATGGAGGCGGCGGTCGCGGCGGCGGCGGCGGCG-3'
AS: 5'-CGCCGCCGCCGCCGCCGCGACCGCCGCCTCCAT-3'
DS2 S: 5'-CTGCTCCTCCTCGTGCTGCTGCTCCCGGGGGCGACG-3'
AS: 5'-CGTCGCCCCCGGGAGCAGCAGCACGAGGAGGAGCAG-3'
DS3 S: 5'-GCGGCGGCGGCGGCGGCGCTCTGTACAAAAGACAAT-3'
AS: 5'-ATTGTCTTTTGTACAGAGCGCCGCCGCCGCCGCCGC-3'
RPA
TβRI DM1 S: 5'-ACCATGGAGGCGGCGGT-3'
AS: 5'-TAATACGACTCACTATAGGGACCACCACCTCCTTATTGC-
AATGGTCCTGA-3'
DM2 S: 5'-ACCATGGAGGCGGCGGT-3'
AS: 5'-TAATACGACTCACTATAGGGACCACCACCTCCAGAGGGT-
GCACATACAA-3'
DM3 S: 5'-AACAAGCTTTCCACCATGGAGGCGGCGGTCGC-3'
AS: 5'-TAATACGACTCACTATAGGGACCACCACCTCCTTCAGCT-
ATACACATGCT-3'
DM4 S: 5'-AACAAGCTTTCCACCATGGAGGCGGCGGTCGC-3'
AS: 5'-TAATACGACTCACTATAGGGACCACCACCTCCATCTCTA-
TGAGCAATGGCT-3'
S, sense primer; AS, antisense primer; RPA, ribonuclease protection assayBMC Molecular Biology 2007, 8:72 http://www.biomedcentral.com/1471-2199/8/72
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cons with a 12-nt linker and a T7 promoter sequences
located in the 3' end of the amplicons. 32P-labeled anti-
sense riboprobes were prepared using a T7 transcription
kit (Ambion) to yield 275, 204, 163, and 102 nt probes
for DM1, DM2, DM3, and DM4, respectively. Total RNA
was extracted from CA1109 effusion tumor cells. Ten µg
of the RNA aliquot was hybridized with individual or
mixed 32P-labeled antisense probe (5 × 104 cpm) for 16 -
18 h at 42°C, digested with RNase A/T1, and resolved on
a 6% acrylamide sequencing gel containing 8 M urea. The
protected RNA fragments were visualized by autoradiog-
raphy.
In vitro transcription/translation
A plasmid (1 µg) coding for wild-type TβRI, DM1 variant,
or luciferase control protein was transcribed and trans-
lated in a coupled reticulocyte lysate system (Promega).
To visualize the translated proteins, [35S] methionine
(1175 Ci/mmol) (PerkinElmer, Boston, MA) was used.
The radiolabeled proteins were resolved in a 10% SDS-
PAGE and autoradiographed with X-ray film.
Cell growth assay
Stably transfected MCF-7 cells (5 × 103) expressing indi-
vidual variants, or vector control cells were seeded and
treated with TGFβ1 for 96 h or not. The cell proliferation
was determined by incubating the cells with 200 µl of
fresh medium containing 1 mg/ml 3-(4,5-dimethylthia-
zol-2-yl)- 2,5-diphenyl tetrazolium bromide (MTT)
(Sigma-Aldrich) for 4 h. After removal of the MTT solu-
tion, the resulting formazan crystals were dissolved com-
pletely in an ethanol/DMSO mixture (1:1), transferred to
the wells of 96-well plates, and quantified using an ELISA
plate reader (Metertech 960, Metertech Inc, Taipei, Tai-
wan) with the absorbance measured at 550 nm. Triplicate
wells were assayed for each experiment and three or four
independent experiments were performed, as indicated in
the figure legends. Data is expressed as the mean of OD550
± standard deviation.
Abbreviations
TGFβ, transforming growth factor-beta; TβRI, TGFβ type I
receptor; 9 A stretch, 9 alanine stretch; TGFBR1-6A, TGFβ
type I receptor with 3 alanine deletion; MTT, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide;
HUVEC, human umbilical endothelial cell; TPA: 12-tetra-
decanoylphorbol-13-acetate; HRP, horseradish peroxi-
dase; PAI-1: plasminogen activator inhibitor 1
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